Acquisition Provides LG Chem’s Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem’s Efforts to Deliver Continued Growth
AVEO Will Have Enhanced Ability to Deliver on its Mission to Improve the Lives of Patients with Cancer
AVEO to Establish and Operate as the U.S. Commercial Foundation for LG Chem Life Sciences’ Oncology Segment
Transaction Price Represents a 43% Premium to AVEO’s Closing Price on October 17, 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.